SinoMab BioScienceのSMA 50
SinoMab BioScienceのSMA 50は何ですか。
SinoMab BioScience LimitedのSMA 50はHKD$1 -20.50%です。
SMA 50の定義は何ですか。
SMA 50は、過去50日間の終値の非加重平均として計算された過去50日間の平均株価である。
Simple moving average of 50 days for a stock is an unweighted moving average over the past 50 days. Moving averages will always exhibit a lag and the longer the period used for averaging the greater the lag will be. Because of the large amounts of data considered when calculating a long-term moving average, it takes a considerable amount of movement in the market to cause the moving average to change its course.
Using a moving average to confirm a trend in price is one of the most basic, yet effecting ways of using the indicator. Moving averages take into account what has already happened and a whole range of past events, which makes them such a good technical analysis tool for trend confirmations. Generally, a long-term moving average that is clearly on the upswing is a confirmation of a bullish trend. Conversely, a long-term moving average that is clearly on the downswing is a confirmation of a bearish trend.
HKSEのセクタHealth CareにおけるSMA 50の企業と比べるSinoMab BioScience
SinoMab BioScienceは何をしますか。
SinoMab BioScience Limited, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of therapeutics for the treatment of immunological diseases, primarily monoclonal antibody (mAb)-based biologics. Its flagship product is SM03, a first-in-target anti-CD22 mAb, which is in Phase III clinical trial for the treatment of rheumatoid arthritis (RA), as well as in various clinical stages for other immunological diseases, such as systemic lupus erythematosus (SLE), Sjogren's syndrome (SS), and non-Hodgkin's lymphoma (NHL). The company also focuses on developing SN1011, a Bruton's tyrosine kinase inhibitor, which is Phase I clinical trial for the treatment of RA, SLE, pemphigus, multiple sclerosis, and other immunological diseases. Its products under preclinical stage comprise SM17 for the treatment of asthma and idiopathic pulmonary fibrosis; SM09 that is used for the treatment of NHL and RA; SM06 for use in treating RA, SLE, and SS; and TNF2 for the treatment of RA. The company operates in Mainland China, the Cayman Islands, and Hong Kong. SinoMab BioScience Limited was incorporated in 2001 and is headquartered in Pak Shek Kok, Hong Kong.
SinoMab BioScienceと類似のsma 50
- Element ASAのSMA 50はkr1 -0.13%です。
- MyFiziqのSMA 50はAUD$1 +93.20%です。
- Leverage Sha Etp 2071のSMA 50は€1 -Inf%です。
- Polytec AssetのSMA 50はHKD$1 +0.00%です。
- Shanghai Dazhong Public Utilities () CoのSMA 50はHKD$1 -19.24%です。
- Beijing Urban Construction Design & Development CoのSMA 50はHKD$1 -4.40%です。
- SinoMab BioScienceのSMA 50はHKD$1 -20.50%です。
- Arch BiopartnersのSMA 50はCAD$1 +0.36%です。
- Asia Pacific Wire & CableのSMA 50は$1 -4.30%です。
- ServiceSource International IncのSMA 50は$1 +0.33%です。
- Blue Star FoodsのSMA 50は$1 -90.95%です。
- B & D StrategicのSMA 50はHKD$1 -18.81%です。
- Unity Biotechnology IncのSMA 50は$1 -7.01%です。